Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Evaluation of Myobrace for Crossbite Correction in Mixed Dentition (Myo vs Frankel)

20. september 2026 oppdatert av: tharwa Ali Mokred AL-awadi, Sana'a University

Evaluation of the Myobrace Appliance in Correcting Crossbite During the Mixed Dentition Stage: A Randomized, Controlled Clinical Trial

This randomized controlled clinical trial will evaluate the effectiveness of the Myobrace appliance in correcting anterior and posterior crossbite in children aged 6 to 10 years during the mixed dentition stage. The study will compare the clinical effects of Myobrace with those of the Frankel III appliance. The study will assess changes in occlusion, skeletal and dentoalveolar relationships, and soft tissue characteristics before and after treatment. The study will also evaluate the effectiveness of the two treatment approaches in improving crossbite correction and related orthodontic outcomes.

Studieoversikt

Status

Aktiv, ikke rekrutterende

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

Crossbite is a common malocclusion in children and may involve anterior or posterior teeth. Early management during the mixed dentition stage may help improve the occlusal relationship and reduce the potential for progression of the malocclusion.

This randomized controlled clinical trial is designed to evaluate the effectiveness of the Myobrace appliance for the correction of crossbite in children aged 6 to 10 years during the mixed dentition stage. The study will compare treatment with the Myobrace appliance with treatment using the Frankel III appliance.

Eligible children with anterior and/or posterior crossbite will be allocated to one of the treatment groups according to the study randomization protocol. Participants will receive the assigned appliance and will be followed throughout the treatment period according to the study protocol.

Treatment effectiveness will be evaluated by comparing clinical and orthodontic measurements obtained before and after treatment. The assessment will include correction of the crossbite and changes in skeletal, dentoalveolar, and soft tissue relationships. Cephalometric analysis will be used to assess relevant skeletal, dentoalveolar, and soft tissue changes.

The study will provide clinical information regarding the effectiveness of Myobrace treatment for crossbite correction during the mixed dentition stage and will allow comparison of its treatment effects with those of the Frankel III appliance.

Studietype

Intervensjonell

Registrering (Faktiske)

40

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Amanat Al Asimah
      • Sanaa, Amanat Al Asimah, Jemen
        • Faculty of Dentistry, Sana'a University

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

6 år til 10 år (Barn)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Clinical diagnosis of anterior crossbite, posterior crossbite, or both.
  • Yemeni children aged 6 to 10 years.
  • Children in the mixed dentition stage.
  • No history of prior orthodontic treatment.

Exclusion Criteria:

  • Children with craniofacial anomalies, such as cleft lip and palate.
  • Children with severe jaw misalignment requiring complex therapy.
  • Children with complete permanent dentition.
  • Children currently undergoing orthodontic treatment
  • Children or parents/guardians unwilling to provide informed consent or participate in the study.
  • Children with predicted or observed poor compliance, including behavioral issues that may interfere with treatment or study procedures.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Myobrace Group

Participants assigned to this arm will receive the Myobrace® Interceptive Class III appliance during the mixed dentition stage. Participants will be instructed to wear the appliance for approximately 1-2 hours during the day and overnight, together with daily myofunctional exercises and instructions regarding nasal breathing, tongue posture, swallowing, and lip competence. Treatment will continue until crossbite correction is achieved or for a maximum of 18 months, whichever occurs first.

Participants will receive the Myobrace® Interceptive Class III appliance during the mixed dentition stage. The appliance will be used according to the study treatment protocol, with instructions for approximately 1-2 hours of daytime wear and overnight wear, together with daily myofunctional exercises and instructions regarding nasal breathing, tongue posture, swallowing, and lip competence. Treatment will continue until crossbite correction is achieved or for a maximum of 18 months, whichever occurs first.

Aktiv komparator: Frankel III Group

Participants assigned to this arm will receive the Frankel III (FR-III) functional regulator during the mixed dentition stage. The appliance will be used according to the clinical treatment protocol. Treatment will continue until crossbite correction is achieved or for a maximum of 18 months, whichever occurs first. Clinical and cephalometric assessments will be performed before and after treatment to evaluate changes in skeletal, dentoalveolar, and occlusal relationships.

Participants will receive the Frankel III (FR-III) functional regulator during the mixed dentition stage. The appliance will be used according to the study treatment protocol. Treatment will continue until crossbite correction is achieved or for a maximum of 18 months, whichever occurs first. Clinical and cephalometric assessments will be performed before and after treatment to evaluate changes in skeletal, dentoalveolar, and occlusal relationships.

Andre navn:
  • FR-III

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in Crossbite Correction Status
Tidsramme: Baseline, and up to 18 months

Change in occlusal crossbite status from baseline to treatment completion, assessed clinically by the presence or absence of anterior and/or posterior crossbite. Complete correction is defined as establishment of a normal anterior and/or posterior buccolingual occlusal relationship according to the type of crossbite present at baseline. The change will be assessed for each participant by comparing the post-treatment crossbite status with the participant's baseline status. The changes will then be compared between the Myobrace and Frankel III groups.

Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in Overjet
Tidsramme: Baseline, and up to 18 months.

Change from baseline in overjet, measured in millimeters (mm) as the horizontal distance between the maxillary and mandibular incisors. The change will be calculated for each participant by comparing the post-treatment overjet value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in Overbite
Tidsramme: Baseline, and up to 18 months.

Change from baseline in overbite, measured in millimeters (mm) as the vertical overlap between the maxillary and mandibular incisors. The change will be calculated for each participant by comparing the post-treatment overbite value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Anterior Crossbite Correction
Tidsramme: Baseline, and up to 18 months.

Correction of anterior crossbite at treatment completion, assessed for each participant by comparing the post-treatment anterior crossbite status with the participant's baseline status. Correction is defined as establishment of a positive or normal horizontal overlap between the maxillary and mandibular anterior teeth that were in crossbite at baseline. The proportion of participants achieving anterior crossbite correction will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Posterior Crossbite Correction
Tidsramme: Baseline, and up to 18 months.

Correction of posterior crossbite at treatment completion, assessed for each participant by comparing the post-treatment posterior crossbite status with the participant's baseline status. Correction is defined as establishment of a normal transverse buccolingual relationship between the maxillary and mandibular posterior teeth that were in crossbite at baseline. The proportion of participants achieving posterior crossbite correction will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in ANB
Tidsramme: Baseline, and up to 18 months.

Change from baseline in the ANB angle, measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment ANB value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in SNA
Tidsramme: Baseline, and up to 18 months.

Change from baseline in the SNA angle, measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment SNA value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in SNB
Tidsramme: Baseline, and up to 18 months.

Change from baseline in the SNB angle, measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment SNB value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in Wits Appraisal
Tidsramme: Baseline, and up to 18 months.

Change from baseline in Wits appraisal, measured in millimeters (mm) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment Wits appraisal value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in SN-MP
Tidsramme: Baseline, and up to 18 months.

Change from baseline in the SN-MP angle, measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment SN-MP value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in SN-OP
Tidsramme: Baseline, and up to 18 months.

Change from baseline in the SN-OP angle, measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment SN-OP value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in Ar-Go-Me (Gonial Angle)
Tidsramme: Baseline, and up to 18 months.

Change from baseline in the Ar-Go-Me (gonial) angle, measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment Ar-Go-Me value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in Y-axis (Por-Gns)
Tidsramme: Baseline, and up to 18 months.

Change from baseline in the Y-axis (Por-Gns) angle, measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment Y-axis value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in FMA
Tidsramme: Baseline, and up to 18 months.

Change from baseline in the FMA (Frankfort-Mandibular Plane Angle), measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment FMA value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in IMPA
Tidsramme: Baseline, and up to 18 months.

Change from baseline in the IMPA (Incisor to Mandibular Plane Angle), measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment IMPA value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in FMIA
Tidsramme: Baseline, and up to 18 months.

Change from baseline in the FMIA (Frankfort-Mandibular Incisor Angle), measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment FMIA value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in S-Go Ratio
Tidsramme: Baseline, and up to 18 months.

Change from baseline in the S-Go ratio, expressed as a percentage (%) on standardized lateral cephalometric radiographs. The ratio represents the posterior facial height (S-Go) relative to the anterior facial height (N-Me). The change will be calculated for each participant by comparing the post-treatment S-Go ratio with the participant's baseline ratio. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in UI-SN
Tidsramme: Baseline, and up to 18 months.

Change from baseline in the UI-SN angle (Upper Incisor to SN Plane), measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment UI-SN value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in Interincisal Angle (U1/L1)
Tidsramme: Baseline, and up to 18 months.

Change from baseline in the interincisal angle (U1/L1), measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment interincisal angle value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in U1/NA Angle
Tidsramme: Baseline, and up to 18 months.

Change from baseline in the U1/NA angle (Upper Incisor to NA), measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment U1/NA angle value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in U1/NA Linear Measurement
Tidsramme: Baseline, and up to 18 months.

Change from baseline in the linear U1/NA measurement (Upper Incisor to NA), measured in millimeters (mm) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment U1/NA linear measurement with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in L1/NB Angle
Tidsramme: Baseline, and up to 18 months

Change from baseline in the L1/NB angle (Lower Incisor to NB), measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment L1/NB angle value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months
Change in L1/NB Linear Measurement
Tidsramme: Baseline, and up to 18 months.

Change from baseline in the linear L1/NB measurement (Lower Incisor to NB), measured in millimeters (mm) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment L1/NB linear measurement with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in Nasolabial Angle (Cotg-Sn-Ls)
Tidsramme: Baseline, and up to 18 months.

Change from baseline in the nasolabial angle (Cotg-Sn-Ls), measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment nasolabial angle value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in Z Angle
Tidsramme: Baseline, and up to 18 months.

Change from baseline in the Z angle (Merritt), measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment Z angle value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in N-Pog-H Line (H Angle)
Tidsramme: Baseline, and up to 18 months.

Change from baseline in the N-Pog-H angle (H angle, Holdaway), measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment N-Pog-H angle value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in Ls-NsPog (U lip /E line)
Tidsramme: Baseline, and up to 18 months

Change from baseline in the Ls-NsPog (upper lip to E-line) measurement, measured in millimeters (mm) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment Ls-NsPog value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months
Change in Li-NsPog (Lower Lip / E-Line)
Tidsramme: Baseline, and up to 18 months.

Change from baseline in the Li-NsPog (lower lip to E-line) measurement, measured in millimeters (mm) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment Li-NsPog value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in Sn-Stm : Stm-Me Ratio
Tidsramme: Baseline, and up to 18 months.

Change from baseline in the Sn-Stm : Stm-Me ratio (Legan and Burstone), expressed as a percentage (%), representing the ratio of the upper lip height (Sn-Stm) to the lower lip and chin height (Stm-Me) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment ratio with the participant's baseline ratio. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in Gl-Sn-Pog (Facial Contour Angle)
Tidsramme: Baseline, and up to 18 months.

Change from baseline in the Gl-Sn-Pog facial contour angle (Glabella-Subnasale-Pogonion), representing the soft tissue angle of facial convexity, measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment Gl-Sn-Pog angle value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in UFH (Upper Facial Height)
Tidsramme: Baseline, and up to 18 months.

Change from baseline in the upper facial height (UFH), measured in millimeters (mm) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment UFH value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in LFH (Lower Facial Height)
Tidsramme: Baseline, and up to 18 months.

Change from baseline in the lower facial height (LFH), measured in millimeters (mm) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment LFH value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in UFH: LFH ratio
Tidsramme: Baseline, and up to 18 months.

Change from baseline in the UFH: LFH ratio (Upper Facial Height to Lower Facial Height), expressed as a percentage (%) on standardized lateral cephalometric radiographs. The ratio represents the upper facial height (UFH) relative to the lower facial height (LFH). The change will be calculated for each participant by comparing the post-treatment UFH:LFH ratio with the participant's baseline ratio. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Studieleder: Dr.Tharwa Alawadi, BDS, MSc, Sana'a University, Faculty of Dentistry
  • Studiestol: Khaled AL-Haddad, Professor, Sana'a University, Faculty of Dentistry

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

23. april 2025

Primær fullføring (Antatt)

1. september 2027

Studiet fullført (Antatt)

1. september 2027

Datoer for studieregistrering

Først innsendt

14. september 2026

Først innsendt som oppfylte QC-kriteriene

20. september 2026

Først lagt ut (Faktiske)

24. september 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

24. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

20. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • PE:01/09/2025

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

Individual participant data will not be shared with other researchers. The study data will be used for the purposes of the current research and reported in aggregate form to protect participant confidentiality and privacy.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .